Description
Opzelura® (Ruxolitinib) Cream 1.5% – Prescription Treatment for Vitiligo & Atopic Dermatitis
Opzelura® Cream 1.5% is an FDA-approved prescription topical treatment formulated with ruxolitinib, a targeted Janus kinase (JAK) inhibitor designed to treat non-segmental vitiligo and mild to moderate atopic dermatitis (eczema) in adults and adolescents 12 years and older.
This non-steroidal topical cream works at the source of inflammation by inhibiting overactive immune signaling in the skin. When used as directed by a healthcare provider, Opzelura® helps restore natural skin tone in vitiligo, reduce redness, itching, and inflammation, and support healthier-looking, more comfortable skin.
Key Benefits of Opzelura® Cream 1.5%
- FDA-approved treatment for vitiligo and atopic dermatitis
- Contains ruxolitinib 1.5%, a clinically proven JAK inhibitor
- Non-steroidal formula suitable for long-term management
- Helps improve skin appearance, texture, and comfort
- Suitable for adults and adolescents (12+)
Product Details
- Product Name: Opzelura® (Ruxolitinib) Cream
- Strength: 1.5%
- Form: Topical cream
- Prescription Required: No
Opzelura® Cream is intended for topical use only and should be used exactly as prescribed by a licensed healthcare provider. Individual results may vary.
